Catalyst Brief

← Calendar

Readoutin 165d

Novo Nordisk A/S — Cagrilintide

Phase 3 primary completion: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide.

Date
May 2027
Type
Readout
Indication
Obesity

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novo Nordisk A/S

  1. Mar2027
  2. Jan2027
    Readoutin 45d
    Novo Nordisk A/S — Insulin icodec
    Phase 3 primary completion: A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes.